At Aesthetics by AM, consultations are relaxed, educational, and medically informed
Extended-release exenatide (Bydureon BCise), given weekly, uses a microsphere suspension that may cause more injection site nodules (reported in 10.5% of patients according to its FDA label) compared to solution-based formulations
Thalassemia major patients using iron chelators showed a reduced plasma thioredoxin level and reduced thioredoxin reductase activity, despite elevated oxidative stress
However, the absence of reported interactions does not constitute proof of safety in all contexts, especially for individuals with hepatic impairment, renal disease, or concurrent medications that affect glucose metabolism
All treatments are administered by licensed nurses using sterile equipment and medical-grade ingredients
At 0.2 mg per unit, 25 units = 5 mg